Table 1.
Baseline characteristics of the patients.
| Characteristic | T+C (n=41) | T+L+C (n=57) | T (n=43) | P value |
|---|---|---|---|---|
| Age | 55.27±10.48 | 53.18±9.25 | 53.5±9.35 | 0.552 |
| Sex | 0.326 | |||
| Male | 34 (82.9%) | 49 (86.0%) | 32 (74.4%) | |
| Female | 7 (17.1%) | 8 (14.0%) | 11 (25.6%) | |
| Etiology | 0.808 | |||
| Hepatitis B | 30 (73.2%) | 44 (77.2%) | 34 (79.1%) | |
| Others | 11 (26.8%) | 13 (22.8%) | 9 (20.9%) | |
| Cirrhosis | 0.929 | |||
| Yes | 30 (73.2%) | 43 (75.4%) | 33 (76.7%) | |
| No | 11 (26.8%) | 14 (24.6%) | 10 (23.3%) | |
| ECOG PS score | 0.269 | |||
| 1 | 24 (58.5%) | 40 (70.2%) | 32 (74.4%) | |
| 2 | 17 (41.5%) | 17 (29.8%) | 11 (25.6%) | |
| Child-Pugh class | 0.911 | |||
| A | 36 (87.8%) | 52 (91.2%) | 39 (90.7%) | |
| B | 5 (12.2%) | 5 (8.8%) | 4 (9.3%) | |
| ALBI Grade | 0.737 | |||
| 1 | 19 (46.3%) | 25 (43.9%) | 19 (44.2%) | |
| 2 | 20 (48.8%) | 31 (54.4%) | 24 (55.8%) | |
| 3 | 2(4.9%) | 1 (1.8%) | 0 (0.0%) | |
| Number of tumors | 0.215 | |||
| 1 | 21 (51.2%) | 33 (57.9%) | 27 (62.8%) | |
| 2 | 5 (12.2%) | 4 (7.0%) | 0 (0.0%) | |
| 3 | 15 (36.6%) | 20 (35.1%) | 16 (37.2%) | |
| Largest tumor size (mm) | 95 (59,110) | 82 (50,111) | 82 (57,98) | 0.430 |
| portal vein invasion | 0.219 | |||
| Yes | 21 (51.2%) | 35 (61.4%) | 30 (69.8%) | |
| No | 20 (48.8%) | 22 (38.6%) | 13 (30.2%) | |
| Extrahepatic metastasis | 0.304 | |||
| Yes | 14 (34.1%) | 23 (40.4%) | 11 (25.6%) | |
| No | 27 (65.9%) | 34 (59.6%) | 32 (74.4%) | |
| AFP level (μg/L) | 0.133 | |||
| ≤400 | 24 (58.5%) | 25 (43.9%) | 16 (37.2%) | |
| >400 | 17 (41.5%) | 32 (56.1%) | 27 (62.8%) |
Data are presented as mean ± standard deviation or n (%) or median (25th-75th), T+L+C, transarterial chemoembolization combined with lenvatinib plus camrelizumab; T+C, transarterial chemoembolization combined with camrelizumab; TACE, transarterial chemoembolization; ECOG-PS, Eastern Cooperative Oncology Group performance status; ALBI, albumin-bilirubin; AFP, alpha-fetoprotein.